Hostname: page-component-7dd5485656-6kn8j Total loading time: 0 Render date: 2025-10-31T13:58:38.083Z Has data issue: false hasContentIssue false
  • English
  • Français

Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients

Published online by Cambridge University Press:  25 November 2014

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Abstract

ISSUE:Many individuals with total blindness can develop a circadian rhythm disorder—called non-24 sleep wake syndrome—because they cannot detect light to resynchronize their sleep–wake cycles. A new melatonin 1 and melatonin 2 agonist tasimelteon improves sleep in these patients, resetting their circadian sleep–wake clocks.

Information

Type
Brainstorms
Information
CNS Spectrums , Volume 19 , Issue 6 , December 2014 , pp. 475 - 478
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Klein, DC, Moore, RY, Reppert, SM. Suprachiasmatic Nucleus: The Mind's Clock. New York: Oxford University Press; 1991.Google Scholar
2.Stahl, SM. Stahl's Essential Psychopharmacology. 4th ed. Cambridge, UK: Cambridge University Press; 2013.Google Scholar
3.Sack, RL, Auckley, D, Auger, RR, etal. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder and irregular sleep-wake rhythm disorder. Sleep. 2007; 30(11): 1484–1501.CrossRefGoogle Scholar
4.Sack, RL, Brandes, RW, Kendall, AR, Lewy, AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. New Engl J Med. 2000; 343(15): 1070–1077.Google Scholar
5.Hayakawa, T, Uchiyama, M, Kamel, Y, etal. Clinical analyses of sighted patients with non-24-hour sleep-wake syndrome: a study of 57 consecutively diagnosed cases. Sleep. 2005; 28(8): 945–952.Google Scholar
6.Emens, JS, Laurie, AL, Songer, JB, Lewy, AJ. Non-24-hour disorder in blind individuals revisited: variability and the influence of environmental time cues. Sleep. 2013; 36(7): 1091–1100.Google Scholar
7.National Sleep Foundation. (Internet). Non-24-hour sleep-wake disorder facts and prevalence. Arlington, VA: National Sleep Foundation. http://sleepfoundation.org/non-24/facts_prevalence.html.Google Scholar
8.Bonacci, JM, Venci, JV, Gandhi, MA. Tasimelteon (Hetlioz): a new melatonin receptor agonist for the treatment of non-24 hour sleep-wake disorder. J Pharm Pract. In press. DOI: 10.1177/0897190014544792.Google Scholar
9.Rajaratnam, SME, Polymeropoulos, MH, Fisher, DM, etal. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomized controlled multicentre trials. Lancet. 2009; 373(9662): 482–491.Google Scholar
10.Stahl, SM. Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectr. 2014; 19(3): 207–212.Google Scholar
11.de Bodinat, C, Guardiola-Lemaitre, B, Mocaër, E, Renard, P, Muñoz, C, Millan, MJ. Agomelatine, the first melatonergic antidepressant: discover, characterization and development. Nat Rev Drug Discov. 2010; 9(8): 628–642.Google Scholar
12.Racagni, G, Riva, MA, Molteni, R, etal. Mode of action of agomelatine: synergy between melatonergic and 5HT2C receptors. World J Biol Psychiatry. 2011; 12(8): 574–587.CrossRefGoogle Scholar